Trial Profile
An Open-Label, Randomized, Multi-panel, Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 25 Sep 2019 Status changed from recruiting to completed.
- 20 Jun 2019 Planned number of patients changed from 108 to 152.
- 20 Jun 2019 Planned End Date changed from 3 May 2019 to 20 Aug 2019.